glp 1 agonist lilly FDA approves Lilly's Foundayo (orforglipron) GLP-1 pill for weight loss Lilly's oral GLP-1 Foundayo (orforglipron)
Description
Found Health's 2026 program details reflect increasing consumer demand for transparency in telehealth weight loss programs, particularly around insurance coverage, medication pathways, and total program cost

According to the EY-Parthenon GLP-1 Consumer Survey (March 2025), 44% of users drink less after starting GLP-1 and 82% keep those habits even after stopping treatment

H., Hong, S
[DOI] [PMC free article] [PubMed] [Google Scholar] 44.Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
"Medicare is not changing the law right now," said Juliette Cubanski, vice president and director of Medicare policy at the health care research nonprofit KFF

Patients with preexisting ischemic optic neuropathy should be advised that there is a small but unproven risk of this agent causing NAION
